Zhang J, et al. – Researchers have initiated the China hemoglobin A1c Metabolism Protection Union Study (CAMPUS) to assess the impact of pitavastatin vs atorvastatin on glucose metabolism, measured by hemoglobin A1c (HbA1c), among 396 Chinese hypertensive prediabetics with dyslipidemias. Study participants will be randomized (1:1) to either daily pitavastatin 2 mg or daily atorvastatin 20 mg, and followed over a 12-month period for assessment of HbA1c levels and other clinical measures. Study drug doses will be doubled for participants who do not meet individual targets 3 months following initiation. Findings of this first-in-kind study may inform development of a clinical strategy and assist in the improvement of primary prevention in patients at risk for diabetes and cardiovascular disease.